Implementation of Smoking Cessation Within NCI NCORP Community Sites Read more about Implementation of Smoking Cessation Within NCI NCORP Community Sites
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients Read more about Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Read more about An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Prediction of Functional Outcomes From Chronic Critical Illness Read more about Prediction of Functional Outcomes From Chronic Critical Illness
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) Read more about Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Read more about Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
An Asthma Mobile Intervention to Promote Patient-Reported Outcomes in Primary Care Read more about An Asthma Mobile Intervention to Promote Patient-Reported Outcomes in Primary Care
Adapting and Expanding the Asthma-Educator App Read more about Adapting and Expanding the Asthma-Educator App
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Read more about Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)